In this exclusive interview with BioPharma BoardRoom, Mike Kadan, Chief Operating Officer of Vector BioMed, shares how the company is reimagining viral vec...
CEO Paul Hudson: Confidence in Full-Year Outlook Paul Hudson, Chief Executive Officer: “We had a strong start in 2025 with sales growth of 9.7%, b...
Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and...
Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commer...
Global pharmaceutical giants have unveiled over $160 billion in fresh U.S. investments within just the past few...
Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,0...
DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior eff...
Intuitive , a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), announced the publication of two st...
Actum Pharma (Actum), a strategy and operating business partner to global biopharma manufacturers, today announces two executive appointments to launch a...
Innovative 6,000-square-foot facility enables clinical and commercial process development support to help cell therapy developers transition from researc...
The Trump administration has launched a bold and controversial national security investigation into America’s heavy reliance on impor...
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered porta...
Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjug...
Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...
© 2025 Biopharma Boardroom. All Rights Reserved.
